Rivastigmine Tartrate
Product Images NDC 27241-090

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 27241-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Stru (Rivastigmine Structure)

Chemical structure diagram of Rivastigmine Tartrate, showing its molecular composition and arrangement including functional groups and the tartrate component.*

FDA Label Image

Fig1 (Rivastigmine Fig1)

A line graph showing mean change from baseline ADAS-Cog rating over 26 weeks of treatment. Three groups are plotted: 6-12 mg dose, 1-4 mg dose, and placebo, indicating trends of clinical improvement or decline over time.*

FDA Label Image

Fig2 (Rivastigmine Fig2)

A cumulative percentage plot showing patients' change from baseline on the ADAS-cog scale across different treatment groups: placebo, 1-4 mg/day, and 6-12 mg/day of Rivastigmine tartrate. Markers indicate 7 points, 4 points improvement, or no change in cognitive scores.*

FDA Label Image

Fig3 (Rivastigmine Fig3)

A bar chart from a CIBIC-Plus rating study showing the percentage of patients distributed across six categories: Markedly Improved, Moderately Improved, Minimally Improved, Unchanged, Minimally Worse, Moderately Worse, and Markedly Worse. The data is grouped by three treatment arms: Placebo, 1-4 mg, and 6-12 mg.*

FDA Label Image

Fig4 (Rivastigmine Fig4)

A line graph depicting mean change from baseline ADAS-cog rating over 26 weeks of treatment for three groups: 6-12 mg, 1-4 mg, and placebo. The vertical axis ranges from clinical decline to clinical improvement. Data points with error bars illustrate changes at multiple time points during treatment.*

FDA Label Image

Fig5 (Rivastigmine Fig5)

A cumulative percentage plot showing change from baseline in ADAS-cog scores for three groups: 6-12 mg, 1-4 mg, and placebo. The x-axis represents change from baseline ranging from -25 to 30, and the y-axis shows cumulative percentage of patients from 0% to 100%. An inset table summarizes mean changes in ADAS-cog scores for each group, with the 6-12 mg group showing the greatest improvement.*

FDA Label Image

Fig6 (Rivastigmine Fig6)

A bar chart showing percentage distribution of patients across categories of CIBIC-Plus ratings, including markedly improved, moderately improved, minimally improved, unchanged, minimally worse, moderately worse, and markedly worse. The chart compares placebo with 1-4 mg and 6-12 mg dosage groups.*

FDA Label Image

Figure7 (Rivastigmine Fig7)

A line graph comparing mean change from baseline in ADAS-cog rating over 24 weeks during treatment with rivastigmine tartrate capsules versus placebo. The graph shows clinical improvement with rivastigmine tartrate and clinical decline with placebo, with data points at 0, 8, 16, and 24 weeks.*

FDA Label Image

Figure8 (Rivastigmine Fig8)

A bar chart comparing the percentage of patients rated by ADCS-CGIC scale across categories from markedly improved to markedly worse for rivastigmine tartrate capsule versus placebo. The chart displays patient outcome percentages for each rating category.*

FDA Label Image

Rivastigmine_1.5_mg (Rivastigmine 1.5 mg 60)

Label for Rivastigmine Tartrate Capsules, USP 1.5 mg by Ajanta Pharma Limited. The label indicates a package of 60 capsules, with storage instructions at 25°C (77°F) and temperature excursions allowed between 15°C to 30°C. Marketed by Ajanta Pharma USA Inc., Bridgewater, NJ, the label includes a barcode and a white, blue, and black color scheme.*

FDA Label Image

Rivastigmine_3_mg (Rivastigmine 3 mg 60)

Label for Rivastigmine Tartrate capsules, USP, 3 mg strength. The label indicates a package size of 60 capsules. It includes storage instructions, marketing and manufacturing information by Ajanta Pharma USA Inc. and Ajanta Pharma Limited, respectively. The label features the National Drug Code (NDC) 27241-091-06 and a barcode.*

FDA Label Image

Rivastigmine_4.5_mg (Rivastigmine 4.5 mg 60)

Rivastigmine Tartrate Capsules USP label showing 4.5 mg strength with a package count of 60 capsules. The label includes storage instructions, manufacturer and marketer details (Ajanta Pharma Limited and Ajanta Pharma USA Inc.), and a barcode. The NDC code is 27241-092-06.*

FDA Label Image

Rivastigmine_6_mg (Rivastigmine 6 mg 60)

Label for Rivastigmine Tartrate Capsules, USP, 6 mg, containing 60 capsules. The label includes storage instructions, dosage note, and states it is marketed by Ajanta Pharma USA Inc. and manufactured by Ajanta Pharma Limited. The label features the NDC number 27241-093-06 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.